Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bossuyt

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
United European Gastroenterology Journal|May 19, 2018
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonistsMartine De Vos, Barbara Dhooghe, Severine Vermeire, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2025
Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn's Disease: A Prospective Observational StudyEdouard Louis, Shaji Sebastian, Britta Siegmund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 4, 2020
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's DiseasePeter Bossuyt, Erwin Dreesen, Jordi Rimola, et al.
International Journal of Colorectal Disease|October 31, 2014
The course of anaemia in children and adolescents with Crohn's disease included in a prospective registryStephanie Van Biervliet, Françoise Smets, Ilse Hofmann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2014
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's diseaseDavid Drobne, Peter Bossuyt, Christine Breynaert, et al.
Journal of Crohn'S & Colitis|January 10, 2023
ECCO Topical Review on Biological Treatment Cycles in Crohn's DiseaseNurulamin M Noor, Paula Sousa, Dominik Bettenworth, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 SurveyGabriele Dragoni, Nik Ding, Krisztina B Gecse, et al.
Journal of Crohn'S & Colitis|January 12, 2024
Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic ReviewCharlotte Wong, Joep van Oostrom, Valerie Pittet, et al.
Journal of Crohn'S & Colitis|May 5, 2022
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world EvidenceCharlotte Wong, Joep van Oostrom, Peter Bossuyt, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
United European Gastroenterology Journal|May 19, 2018
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonistsMartine De Vos, Barbara Dhooghe, Severine Vermeire, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 15, 2025
Long-Term Safety of Vedolizumab in Patients With Ulcerative Colitis/Crohn's Disease: A Prospective Observational StudyEdouard Louis, Shaji Sebastian, Britta Siegmund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 4, 2020
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's DiseasePeter Bossuyt, Erwin Dreesen, Jordi Rimola, et al.
International Journal of Colorectal Disease|October 31, 2014
The course of anaemia in children and adolescents with Crohn's disease included in a prospective registryStephanie Van Biervliet, Françoise Smets, Ilse Hofmann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 29, 2014
Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's diseaseDavid Drobne, Peter Bossuyt, Christine Breynaert, et al.
Journal of Crohn'S & Colitis|January 10, 2023
ECCO Topical Review on Biological Treatment Cycles in Crohn's DiseaseNurulamin M Noor, Paula Sousa, Dominik Bettenworth, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 SurveyGabriele Dragoni, Nik Ding, Krisztina B Gecse, et al.
Journal of Crohn'S & Colitis|January 12, 2024
Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic ReviewCharlotte Wong, Joep van Oostrom, Valerie Pittet, et al.
Journal of Crohn'S & Colitis|May 5, 2022
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world EvidenceCharlotte Wong, Joep van Oostrom, Peter Bossuyt, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, et al.
Pageof 14